$RILY

B. Riley Financial (NASDAQ:RILY) Upgraded at Wall Street Zen

Wall Street Zen has upgraded B. Riley Financial (RILY) from a "hold" to a "buy" rating, though Weiss Ratings maintains a "sell (e+)" and the MarketBeat consensus remains "Sell." The stock recently traded down 9.1% with a market cap of $255.8 million and a P/E of 1.19. Institutional ownership stands at 50.2%, with several funds increasing their stakes.

Original reporting
MarketBeat · MarketBeat
Published Jan 31, 2026, 7:12 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 31, 2026, 8:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
B. Riley Financial (NASDAQ:RILY) Upgraded at Wall Street Zen — source image
Decision brief

The 30-second read

$RILYBearishMed
01

Why it matters

The upgrade by Wall Street Zen could serve as a catalyst for a short-term rebound, but conflicting analyst opinions temper enthusiasm.

02

Market read

The news is relevant primarily to traders and investors holding or considering RILY, with limited impact on broader markets.

03

What to watch

Potential upcoming earnings reports or macroeconomic factors could override the impact of this upgrade, so traders should monitor broader market conditions.

Timing: short-term (1-3 days)

Background

B. Riley Financial (RILY) experienced a 9.1% decline recently, possibly due to broader market movements or company-specific factors.

Company-level read

Ticker impact

$RILYBearishMedium confidence
Context

The news pertains directly to B. Riley Financial (RILY), which has been upgraded by Wall Street Zen, indicating a potential positive shift in sentiment.

Expected impact

Moderate upward price movement expected over the next 1-3 trading days, contingent on market reaction to the upgrade.

Evidence & confidence

The upgrade by Wall Street Zen could trigger short-term buying interest, but the conflicting ratings and recent 9.1% decline suggest caution. Technical analysis shows the stock is near a support level, which could serve as a rebound point.

Market effects

The upgrade may positively influence sentiment within the financial services sector, potentially benefiting related stocks.

Limited; the news is specific to a U.S.-based company and does not suggest broader regional effects.

Negligible; the impact is localized to the company's stock and sector.

Counterpoint

The conflicting ratings and recent decline suggest the upgrade may be a short-term anomaly rather than a sustained positive shift.

Key entities

  • B. Riley Financial

    A financial services company providing investment banking, trading, and brokerage services.

Related articles

$RILYMed

BRC Group Holdings, Inc. (RILY): Results of Operations and Financial Condition

BRC Group Holdings, Inc. (RILY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE BRC Group Holdings, Inc. Reports Second Quarter 2026 Financial Results Second Quarter 2026 Net Income Available to Common Shareholders of $18.5 Million; Second Quarter 2026 Adjusted EBITDA of $61.3 Million; Operating Adjusted EBITDA of $66.0 Million LOS ANGE

$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

$EXCMed

Why Exelon's CFO is stepping into a new strategy role

Exelon's CFO Jeanne Jones transitions to a new role as EVP of finance and strategy on Oct. 5, focusing on long-term strategy and capital allocation. Robert Kleczynski will succeed Jones as CFO. Exelon reported Q2 revenue of $5.97 billion, up 10% YoY, beating estimates. The company is investing in infrastructure amid rising electricity demand and pressure to keep customer bills affordable.

$WMTMedAI 8/10

Walmart to Build $1.3 Billion Fulfillment Center in Georgia

Walmart plans to build a $1.3 billion automated fulfillment center in Carnesville, Georgia, creating 1,000 jobs and expanding shipping capacity. The 1.5 million-square-foot facility is part of Walmart's strategy to meet evolving customer expectations for speed and convenience. Construction is expected to begin in late 2026.